Your company account is blocked and you cannot place orders. If you have questions, please contact your company administrator.

SKF-83566 - 99%, high purity , CAS No.99295-33-7

  • ≥99%
Item Number
S647449
Grouped product items
SKUSizeAvailabilityPrice Qty
S647449-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$95.90
S647449-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$150.90
S647449-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$270.90

Basic Description

SynonymsSKF-83566 | 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1h-3-benzazepin-7-ol | SK83566 | SK-83566 | CHEBI:91747 | PDSP1_000503 | 8-Bromo-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol | 8-Bromo-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-3-benza
Specifications & Purity≥99%
Biochemical and Physiological MechanismsSKF-83566 is a potent,xa0blood-brain permeable and orally active D1-like dopamine receptor (D1DR) antagonist and a weaker competitive antagonist at the vascular 5-HT 2 receptor ( K i =11 nM). SKF-83566 is a competitive DAT (dopamine transporter)
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
Product Description

SKF-83566 is a potent, blood-brain permeable and orally active D1-like dopamine receptor (D1DR) antagonist and a weaker competitive antagonist at the vascular 5-HT 2 receptor ( K i =11 nM) SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC 50 of 5.7 μM SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC2) over AC 1 and AC 5 in the isolated rabbit thoracic aorta. SKF-83566 can be used for research of parkinson’s disease and nicotine craving alleviation.

In Vitro

SKF-83566 (0.1 μM-10 μM) causes a concentration-dependent increase in peak evoked extracellular DA concentration ([DA] o )?evoked by single-pulse stimulation, with a maximum 65% increase in peak evoked [DA] o with 5 μM. The EC 50 value of this effect of SKF-83566 is 1.3 μM. SKF-83566 inhibited [ 3 H]DA uptake with an IC 50 ?of 5.73 μM. Moreover, SKF-83566 more potently inhibits the binding of [ 3 H]CFT, with an IC 50 ?of 0.51 μM in [ 3 H]DA uptake and [ 3 H]CFT binding studies. Similarly, in LLc-PK-rDAT cell, SKF-83566 also inhibits [ 3 H]CFT binding with an IC 50 ?of 0.77 μM in LLc-PK-rDAT cell membrane preparations. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SKF 83566 (oral administration; 20 μg/mL; 7 days) alone has no effects on altering LTP (115%). However, combinnation of SKF 83566 and nicotine significantly blocks the enhancement of long-term synaptic potentiation (LTP) induced by pretreatment with nicotine (SKF 83566+nicotine+cocaine, 120%; nicotine+cocaine, 143%) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL6/J mice (6- to 9-wk-old) Dosage: 20 µg/mL (Together with nicotine for 7 d, followed by the injection of cocaine) Administration: Oral administration; 7 days Result: Blocked nicotine and cocaine-induced facilitation of LTP.

Form:Solid

IC50& Target:D 1 Receptor D 5 Receptor 5-HT 2 Receptor 11 nM (Ki)

Associated Targets(Human)

DRD1 Tclin D(1A) dopamine receptor (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
DRD5 Tchem D(1B) dopamine receptor (3 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
DRD2 Tclin Dopamine D2 receptor (23596 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD1 Tclin Dopamine D1 receptor (9720 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD5 Tchem Dopamine D5 receptor (1597 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADCY3 Tbio Adenylate cyclase type III (24 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADCY1 Tchem Brain adenylate cyclase 1 (372 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TDP1 Tchem Tyrosyl-DNA phosphodiesterase 1 (345557 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Adcy2 Adenylate cyclase type II (26 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
J774.A1 (2436 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences
Dopamine D2 receptor antagonistANTAGONISTALA217Dopamine D2 receptorSINGLE PROTEINHomo sapiens

ISBN: [1]


PubMed: [1]


Dopamine D2 receptor antagonistANTAGONISTALA217Dopamine D2 receptorSINGLE PROTEINHomo sapiens

ISBN: [1]


PubMed: [1]


Dopamine D2 receptor antagonistANTAGONISTALA217Dopamine D2 receptorSINGLE PROTEINHomo sapiens

PubMed: [1] , [2] , [3]


Wikipedia: [1]


Dopamine D2 receptor antagonistANTAGONISTALA217Dopamine D2 receptorSINGLE PROTEINHomo sapiens

PubMed: [1] , [2] , [3] , [4]


Wikipedia: [1]


Dopamine D2 receptor modulatorMODULATORALA217Dopamine D2 receptorSINGLE PROTEINHomo sapiens

PubMed: [1] , [2]


Dopamine D2 receptor antagonistANTAGONISTALA217Dopamine D2 receptorSINGLE PROTEINHomo sapiens

DailyMed: [1]


ISBN: [1]


Dopamine D2 receptor antagonistANTAGONISTALA217Dopamine D2 receptorSINGLE PROTEINHomo sapiens

PubMed: [1] , [2] , [3]


Wikipedia: [1]


Dopamine D2 receptor agonistAGONISTALA217Dopamine D2 receptorSINGLE PROTEINHomo sapiens

FDA: [1]


Wikipedia: [1]


Dopamine D2 receptor antagonistANTAGONISTALA217Dopamine D2 receptorSINGLE PROTEINHomo sapiens

DailyMed: [1]


ISBN: [1]


Dopamine D2 receptor antagonistANTAGONISTALA217Dopamine D2 receptorSINGLE PROTEINHomo sapiens

PubMed: [1] , [2] , [3]


Wikipedia: [1]


Names and Identifiers

IUPAC Name 8-bromo-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
INCHI InChI=1S/C17H18BrNO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3
InChi Key XFTVOHWWEQGXLS-UHFFFAOYSA-N
Canonical SMILES CN1CCC2=CC(=C(C=C2C(C1)C3=CC=CC=C3)O)Br
Isomeric SMILES CN1CCC2=CC(=C(C=C2C(C1)C3=CC=CC=C3)O)Br
Alternate CAS 99295-33-7
PubChem CID 1243
MeSH Entry Terms 1H-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-;1H-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-, (S-isomer);7-bromo-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine;8-bromo-2,3,4,5-tetrahydro-3-methyl
Molecular Weight 332.23

Certificates

C of A & Other Certificates

Chemical and Physical Properties

SolubilityDMSO : 33.33 mg/mL (100.32 mM; Need ultrasonic)

Related Documents

Solution Calculators